Bimekizumab in Patients with Moderate-to-Severe Hidradenitis Suppurativa: 48-Week Efficacy and Safety from BE HEARD I & II, Two Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Studies
Authors: Alexa B. Kimball, Christos C. Zouboulis, Christopher Sayed, Joslyn S. Kirby, Errol Prens, John R. Ingram, Amit Garg, Robert Rolleri, Edward Muller, Paulatsya Joshi, Gregor Jemec
< PREVIOUS POSTER NEXT POSTER >
